Crossmark

A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma

Crossref DOI link: https://doi.org/10.1186/s13014-018-0992-3

Published Online: 2018-03-20

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Correa, Rohann J. M.

Ahmad, Belal

Warner, Andrew

Johnson, Craig

MacKenzie, Mary J.

Pautler, Stephen E.

Bauman, Glenn S.

Rodrigues, George B.

Louie, Alexander V.
Funding

Funding for this research was provided by:

Schulich School of Medicine and Dentistry (Clinician Scientist Award)
License Information

Text and Data Mining valid from 2018-03-20
More Information

Article History

Received: 6 January 2018

Accepted: 6 March 2018

First Online: 20 March 2018

Ethics approval and consent to participate

: Ethics approval for this study was provided by the Western University Human Studies Research Ethics Board (REB# 15680). All study participants provided written consent to participate in this trial.

: All study participants provided written consent which included consent for the publication of trial results.

: Dr. Louie has received speaker’s honoraria from Varian Medical Systems, Inc.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below